In Treatment for Muscle Invasive Bladder Cancer

Navigating muscle-invasive bladder cancer treatment? Explore the pros and cons of radical cystectomy versus bladder preservation to make an informed decision.

If doctors are treating you for muscle-invasive bladder cancer (MIBC), your treatment plan may include pembrolizumab (P) in combination with enfortumab vedotin-ejfv (EV). In July 2026, the U.S. Food and Drug Administration (FDA) expanded its approval of this combination as treatment before surgery, followed by treatment after bladder removal surgery, to include people with MIBC […]

A diagnosis of muscle-invasive bladder cancer (MIBC) sets a lot in motion quickly. As a patient, you’ll be immersed in imaging scans, staging conversations, and a treatment timeline that typically leads toward chemotherapy and a major surgery called radical cystectomy. In the middle of that whirlwind, one of the most useful things a patient can […]

Discover why neoadjuvant chemotherapy before radical cystectomy is the gold standard for muscle-invasive bladder cancer to improve survival and treatment outcomes.

Take control of your MIBC journey. Learn the essential questions to ask your care team about treatment options, surgery, and clinical trials for bladder cancer.

For people with high-risk muscle-invasive urothelial carcinoma, including bladder cancer, treatment doesn’t always end after surgery. Even after the bladder and surrounding tissue are removed, there’s still a risk that cancer can come back. That’s why some patients receive adjuvant therapy, treatment given after surgery to lower the risk of recurrence. The AMBASSADOR trial found […]

On July 10th, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab,Keytruda in combination with enfortumab vedotin (Padcev,) for use both before and after bladder removal surgery (radical cystectomy) in adults with muscle-invasive bladder cancer (MIBC). The approval is significant for two reasons: it introduces a treatment strategy that spans both the neoadjuvant (before […]

The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for certain patients with muscle-invasive bladder cancer (MIBC) after bladder removal surgery (cystectomy). The FDA also approved Signatera CDx as the companion diagnostic test used to identify eligible patients. This approval marks an important step toward more personalized […]

A bladder cancer diagnosis is hard enough. Learning it has crossed into muscle tissue — that it’s now muscle-invasive bladder cancer (MIBC) — hits differently. The urgency escalates. The treatment conversation changes completely. But here’s what matters most right now: understanding your full range of muscle-invasive bladder cancer treatment options puts you back in control. […]

There’s encouraging news for people diagnosed with muscle-invasive bladder cancer (MIBC). New research presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium showed that a combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) may help patients live longer and reduce the risk of the cancer returning, which is outperforming the current standard […]

Radical cystectomy, the surgical removal of the bladder, is one of the standard treatments for muscle-invasive bladder cancer. Life after bladder removal is undeniably different. Your body works in a new way and routines shift. The emotional weight of that change is real and valid. With some adjustment, life after bladder removal can still be […]